Floatz logo

BUTYRIN

Parkinson Disease Dementia

Prabesh KanelSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Parkinson Disease Dementia cohort.

Asset / SponsorPhaseRating
Rivastigmine
University of Maryland, Baltimore
Phase 4BB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Virginia Commonwealth University
Phase 4BB
BLARCAMESINE
Anavex Life Sciences Corp.
Phase 2B
FOSGONIMETON
LeonaBio
Phase 2CC

Same molecule, other indications

BUTYRIN is also rated in:

cancer of unknown primary siteDormant
CC
Indicative ·
46 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
46 / 100
View asset →
prostate cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →